GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Effect of rFVIIa for Treatment of ICH on Health Plan Budgets

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Select+from+History&query_key=1&WebEnv=0Y7...

>>
Manag Care Interface. 2006 Nov;19(11):39-45.

Earnshaw SR, Wilson MR, Joshi AV.

RTI Health Solutions, Research Triangle Park, North Carolina 27709, USA.

Treating patients with intracerebral hemorrhage (ICH) using recombinant activated factor VII (rFVIla) has been found to improve survival and functional outcome. To examine how the introduction of rFVIla 80 mcg/kg as a treatment for ICH affects the budget of a health plan, a decision-analysis model was developed which considered both short-term hospitalization costs and long-term management of disability.

Assuming a health plan enrollment of 1 million members and initial rFVIla uptake of 50% in appropriate patients, the annual health plan cost may be expected to increase by $64,781 ($0.005 per member per month). With a 5% increase in uptake each year, the annual health plan's cost may decrease compared with the current budget within three years.

The implications for this sample health plan's budget are modest in the first year, and a reduction in costs is expected within three years owing to improved functional outcomes of patients.
<<